Clinical Trials | June 02, 2026
BioNTech and Bristol Myers Squibb drug shows strong early signal in lung cancer trial
The safety profile was described as manageable, though not without notable toxicities
The safety profile was described as manageable, though not without notable toxicities
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
